Tenofovir disoproxil fumarate - A review of its use in the management of HIV infection

被引：59

作者：

Lyseng-Williamson, KA ^{[1
]}

Reynolds, NA ^{[1
]}

Plosker, GL ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland 1311, New Zealand

来源：

DRUGS | 2005年 / 65卷 / 03期

关键词：

tenofovir disoproxil fumarate; HIV infection; nucleotide reverse transcriptase inhibitors; pharmacodynamics; pharmacokinetics; therapeutic use; tolerability;

D O I：

10.2165/00003495-200565030-00006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tenofovir disoproxil fumarate (tenofovir DF; Viread(R)), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.

引用

页码：413 / 432

页数：20

共 78 条

[1] Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].